As seen in Figure 1D–1F, the CT26/HER2 tumor formation had no impact on the 4T1.2/HER2 tumor regression, suggesting that antitumor immunity could be induced by 4T1.2/HER2 cells even in a CT26/HER2 tumor-derived in vivo environment. The gene discussed is ERBB2; the disease is neoplasm.